Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome
- Mayo Clinic, United States
- Sanford Burnham Prebys Medical Discovery Institute, United States
- University of California San Diego, United States
Abstract
Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multi-disciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in generic human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing Drosophila and zebrafish hearts revealed that LDL receptor-related protein LRP2 is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to patents the proband's iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps towards deciphering oligogenic underpinnings of CHDs, including maladaptive left hearts.
Data availability
Sequencing data are deposited in the NCBI Sequence Read Archive (SRA) database with accession numbers: SRS1417684 (proband iPSCs), SRS1417685 (paternal iPSCs), SRS1417686 (maternal iPSCs), SRS1417695 (proband d25 differentiated cells), SRS1417696 (paternal d25 differentiated cells), SRS1417714 (maternal d25 differentiated cells)
Article and author information
Author details
Funding
Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Mayo Clinic Foundation, Rochester, MN (SAN-233970)
- Alexandre R Colas
- Rolf Bodmer
National Institutes of Health (HL054732)
- Rolf Bodmer
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: SBP has retained the services of a veterinarian who is a diplomat of the American College of Laboratory Animal Medicine. Close contact with Animal Facility personnel is maintained through telephone calls and on-campus visits once a week. This person is a member of the Institute's Animal Care and Use Committee (IACUC)and attends monthly meetings. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the Institute's Animal Care and Use Program, which is accredited by AAALAC International, and a Multiple Project Assurance A3053-1 is on file in the OLAW, DHHS. The protocol was approved by SBP IACUC (Permit Number: 19-087). Animals are euthanized after filming hearts by an overdose of anesthetic (3-aminobenzoic acid ethyl ester (MS-222) at 250-300 mg/L.
Human subjects: Written informed consent was obtained for the index family and an HLHS cohort, under a research protocol approved by the Mayo Clinic Institutional Review Board (11-000114 "Genetic Investigations in Hypoplastic Left Heart Syndrome").
Copyright
© 2020, Theis et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,366
- views
-
- 308
- downloads
-
- 31
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome
eLife 9:e59554.
https://doi.org/10.7554/eLife.59554
Further reading
-
- Genetics and Genomics
One of the goals of synthetic biology is to enable the design of arbitrary molecular circuits with programmable inputs and outputs. Such circuits bridge the properties of electronic and natural circuits, processing information in a predictable manner within living cells. Genome editing is a potentially powerful component of synthetic molecular circuits, whether for modulating the expression of a target gene or for stably recording information to genomic DNA. However, programming molecular events such as protein-protein interactions or induced proximity as triggers for genome editing remains challenging. Here, we demonstrate a strategy termed ‘P3 editing’, which links protein-protein proximity to the formation of a functional CRISPR-Cas9 dual-component guide RNA. By engineering the crRNA:tracrRNA interaction, we demonstrate that various known protein-protein interactions, as well as the chemically induced dimerization of protein domains, can be used to activate prime editing or base editing in human cells. Additionally, we explore how P3 editing can incorporate outputs from ADAR-based RNA sensors, potentially allowing specific RNAs to induce specific genome edits within a larger circuit. Our strategy enhances the controllability of CRISPR-based genome editing, facilitating its use in synthetic molecular circuits deployed in living cells.
-
- Genetics and Genomics
Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a yeast imaging-based screen, we identified 84 potential synphilin-1 (SY1) IB regulators and isolated the conserved sphingolipid metabolic components in the most enriched groups. Furthermore, we show that, in both yeast cells and mammalian cells, SY1 IBs are associated with mitochondria. Pharmacological inhibition of the sphingolipid metabolism pathway or knockout of its key genes results in a delayed IB maturation and increased SY1 cytotoxicity. We postulate that SY1 IB matures by association with the mitochondrion membrane, and that sphingolipids stimulate the maturation via their membrane-modulating function and thereby protecting cells from SY1 cytotoxicity. Our findings identify a conserved cellular component essential for IB maturation and suggest a mechanism by which cells may detoxify the pathogenic protein aggregates through forming mitochondrion-associated IBs.
